Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 17/20 | 0.47 |
| ▸ | GIPR | P48546 | 16/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585375 | 0.91 | CPB1 (0.46) | GCGRGIPRKDM4EMEN1ALDH1A1 | |
| SCHEMBL5585521 | 0.90 | GCGR (0.46) | GCGRGIPRKDM4EMEN1ALDH1A1 | |
| SCHEMBL5585426 | 0.85 | GCGR (0.55) | GCGRGIPRKDM4EMEN1ALDH1A1 | |
| SCHEMBL5585559 | 0.82 | GCGR (0.46) | GCGRGIPRKDM4EMEN1ALDH1A1 | |
| SCHEMBL5585462 | 0.81 | GCGR (0.51) | GCGRGIPRKDM4EMEN1ALDH1A1 | |
| SCHEMBL5585508 | 0.80 | CPB1 (0.45) | GCGRGIPRKDM4EMEN1KMT2A | |
| SCHEMBL5585561 | 0.80 | GCGR (0.53) | GCGRGIPRKDM4EMEN1ALDH1A1 | |
| SCHEMBL5585685 | 0.80 | KDM4E (0.45) | GCGRGIPRKDM4EMEN1ALDH1A1 | |
| SCHEMBL5585535 | 0.79 | GCGR (0.38) | GCGRGIPRKDM4EMEN1ALDH1A1 | |
| SCHEMBL5585652 | 0.79 | GCGR (0.50) | GCGRGIPRKDM4EMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | GCGR 317/4885GIPR 195/4885KDM4E 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.